First Citizens Bank & Trust CO Supernus Pharmaceuticals, Inc. Transaction History

First Citizens Bank & Trust CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 15, 2019	SELL	$30.84 - $49.51 $130,545 - $209,575	-4,233 Closed	0 $0
Q3 2018 Oct 18, 2018	SELL	$42.7 - $56.55 $768 - $1,017	-18 Reduced 0.42%	4,233 $213,000
Q2 2018 Jul 11, 2018	SELL	$44.1 - $59.85 $28,753 - $39,022	-652 Reduced 13.3%	4,251 $254,000
Q1 2018 Apr 11, 2018	BUY	$37.15 - $46.9 $182,146 - $229,950	4,903 New	4,903 $225,000

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of First Citizens Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on First Citizens Bank & Trust CO with notifications on news.